Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
Disposition to issuerStock Options (Right to buy) · Derivative | 1,505 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,995 Underlying: Common Stock · 1,505 shares Expires 2022-08-07 F3 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 5,995 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
Disposition to issuerRestricted Stock Units · Derivative | 241 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 959 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241 Underlying: Common Stock · 959 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
Tax withholdingCommon Stock | 438 | $180.14 | $78,901.32 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 959 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
Disposition to issuerStock Options (Right to buy) · Derivative | 3,762 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · derivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,988 Underlying: Common Stock · 3,762 shares Expires 2022-08-07 F3 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 14,988 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
Disposition to issuerRestricted Stock Units · Derivative | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 602 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 2,398 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 2,398 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · derivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 Underlying: Common Stock · 2,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 2,398 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 2,398 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
Tax withholdingCommon Stock | 1,094 | $180.14 | $197,073.16 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,382 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 2,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:21 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 8,000 | $160.00 | $1,280,000.00 |
DisclosureSEC source: 0001562180-18-002938 · primarydocument.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,472 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2018. F2 · balance_after: Includes (i) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; (ii) 3,841 shares for which the risks of forfeiture will lapse on August 7, 2018; and (iii) 11,102 shares for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2018 and August 18, 2019; and (iv) 4,731 shares each which risks of forfeiture will lapse on August 9, 2018 and August 9, 2019; and (v) 4,732 shares for which risks of forfeiture will lapse on August 9, 2020 Read SEC document |
| May 04, 2018 Filed May 11, 2018 20:16 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
SaleCommon Stock | 1,136 | $145.19 | $164,931.75 |
DisclosureSEC source: 0001562180-18-002455 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,266 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:22 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
GrantStock Option (Right to Buy) · Derivative | 7,348 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001562180-18-002166 · primarydocument.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 7,348 shares Expires 2025-05-01 F4 · derivative.exercise_date: 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:22 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
GrantStock Option (Right to Buy) · Derivative | 2,652 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001562180-18-002166 · primarydocument.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652 Underlying: Common Stock · 2,652 shares Expires 2025-05-01 F3 · derivative.exercise_date: 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:22 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
GrantRestricted Stock · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002166 · primarydocument.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests 1,667 on 5/1/2019, 1,666 shares on 5/1/2020 and 1,667 on 5/1/2021 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC |
Dinarello Charles ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $65.47 | $0.00 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · derivative · entry 13 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC |
Dinarello Charles ADirector
|
SaleCommon Stock | 2,505 | $136.36 | $341,581.80 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · nonDerivative · entry 3 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,212 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.03 to $136.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC |
Dinarello Charles ADirector
|
SaleCommon Stock | 2,495 | $135.76 | $338,721.20 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · nonDerivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,717 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $135.875, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:02 UTC |
Dinarello Charles ADirector
|
Exercise / conversionCommon Stock | 5,000 | $65.47 | $327,350.00 |
DisclosureSEC source: 0000914190-18-000041 · edgar.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:41 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 5,000 | $0.00 Strike: $63.03 | $0.00 |
DisclosureSEC source: 0001562180-17-003467 · primarydocument.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:41 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 5,000 | $130.18 | $650,907.00 |
DisclosureSEC source: 0001562180-17-003467 · primarydocument.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.24 to $131.85, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:41 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 5,000 | $63.03 | $315,150.00 |
DisclosureSEC source: 0001562180-17-003467 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:16 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to buy) · Derivative | 78,228 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003387 · primarydocument.xml · derivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,228 Underlying: Common Stock · 78,228 shares Expires 2024-08-09 F4 · derivative.exercise_date: Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:16 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to buy) · Derivative | 117,342 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003387 · primarydocument.xml · derivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,342 Underlying: Common Stock · 117,342 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:16 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 21,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003387 · primarydocument.xml · derivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,291 Underlying: Common Stock · 21,291 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:16 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantCommon Stock | 14,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003387 · primarydocument.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,472 F1 · balance_after: Includes (i) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; (ii) 3,841 shares for which the risks of forfeiture will lapse on August 7, 2018; and (iii) 11,102 shares for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2018 and August 18, 2019; and (iv) 4,731 shares each which risks of forfeiture will lapse on August 9, 2018 and August 9, 2019; and (v) 4,732 shares for which risks of forfeiture will lapse on August 9, 2020. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:10 UTC |
STEER RANDOLPH CDirector
|
GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003385 · primarydocument.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:10 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003385 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,712 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:14 UTC |
Seth AlpnaDirector
|
GrantStock Options (Right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003386 · primarydocument.xml · derivative · entry 2 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2017) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:14 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003386 · primarydocument.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:08 UTC |
Bazan J. FernandoChief Technical Officer
|
GrantStock Options (Right to buy) · Derivative | 12,119 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003384 · primarydocument.xml · derivative · entry 3 Bazan J. Fernando · CIK 0001583204 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,119 Underlying: Common Stock · 12,119 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests 3,029 shares on 8/9/2018 and 3,030 shares each on 8/9/2019, 8/9/2020 and 8/9/2021 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:08 UTC |
Bazan J. FernandoChief Technical Officer
|
GrantStock Options (Right to buy) · Derivative | 9,089 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003384 · primarydocument.xml · derivative · entry 2 Bazan J. Fernando · CIK 0001583204 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,089 Underlying: Common Stock · 9,089 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:08 UTC |
Bazan J. FernandoChief Technical Officer
|
GrantRestricted Stock Units · Derivative | 1,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003384 · primarydocument.xml · derivative · entry 1 Bazan J. Fernando · CIK 0001583204 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,649 Underlying: Common Stock · 1,649 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:03 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003383 · primarydocument.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2018) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:03 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003383 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC |
Gavin Robert M.Sen. VP Protein Platforms
|
GrantStock Options (Right to buy) · Derivative | 14,323 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003381 · primarydocument.xml · derivative · entry 4 Gavin Robert M. · CIK 0001608023 · Sen. VP Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,323 Underlying: Common Stock · 14,323 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC |
Gavin Robert M.Sen. VP Protein Platforms
|
GrantStock Options (Right to buy) · Derivative | 10,742 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003381 · primarydocument.xml · derivative · entry 3 Gavin Robert M. · CIK 0001608023 · Sen. VP Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,742 Underlying: Common Stock · 10,742 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC |
Gavin Robert M.Sen. VP Protein Platforms
|
GrantRestricted Stock Units · Derivative | 1,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003381 · primarydocument.xml · derivative · entry 2 Gavin Robert M. · CIK 0001608023 · Sen. VP Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949 Underlying: Common Stock · 1,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to buy) · Derivative | 12,670 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003382 · primarydocument.xml · derivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,670 Underlying: Common Stock · 12,670 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vest 3,167 shares each on 8/9/2018, 8/9/2019 and 3,168 shares each on 8/9/2020, 8/9/2021. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to buy) · Derivative | 9,503 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003382 · primarydocument.xml · derivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,503 Underlying: Common Stock · 9,503 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003382 · primarydocument.xml · derivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,724 Underlying: Common Stock · 1,724 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC |
Gould Kevin SSVP Clinical Controls
|
GrantStock Options (Right to buy) · Derivative | 14,323 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003380 · primarydocument.xml · derivative · entry 4 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,323 Underlying: Common Stock · 14,323 shares Expires 2024-08-09 F4 · derivative.exercise_date: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC |
Gould Kevin SSVP Clinical Controls
|
GrantStock Options (Right to buy) · Derivative | 10,742 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003380 · primarydocument.xml · derivative · entry 3 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,742 Underlying: Common Stock · 10,742 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC |
Gould Kevin SSVP Clinical Controls
|
GrantRestricted Stock Units · Derivative | 1,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003380 · primarydocument.xml · derivative · entry 2 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949 Underlying: Common Stock · 1,949 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantStock Options (Right to buy) · Derivative | 15,976 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003379 · primarydocument.xml · derivative · entry 4 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,976 Underlying: Common Stock · 15,976 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantStock Options (Right to buy) · Derivative | 11,982 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003379 · primarydocument.xml · derivative · entry 3 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,982 Underlying: Common Stock · 11,982 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantRestricted Stock Units · Derivative | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003379 · primarydocument.xml · derivative · entry 2 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:55 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to buy) · Derivative | 32,613 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003378 · primarydocument.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,613 Underlying: Common Stock · 32,613 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests 8,153 shares each on 8/19/2018, 8/9/2019, 8/9/2020 and 8,154 on 8/9/2021 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:55 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to buy) · Derivative | 24,460 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003378 · primarydocument.xml · derivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,460 Underlying: Common Stock · 24,460 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:55 UTC |
Hippel JamesChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003378 · primarydocument.xml · derivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Underlying: Common Stock · 4,438 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.